Satvik Munshi, MD
Interventional Pain Medicine · Harvey, LANPI 1124298344
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $453 and has fallen 50.2% since, to $225 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in LA, where the typical reported total is $4,761.
Across 78 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Forte Bio-pharma LLC$380
- Nevro Corp.$189
- Collegium Pharmaceutical, Inc.$168
- Medtronic$153
- Merck$125
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$110
- plus $531 from 16 others
What the payments were for
- Food & beverage$1,654100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Forte Bio-pharma LLC | 25 | $380 |
| Nevro Corp. | 4 | $189 |
| Collegium Pharmaceutical, Inc. | 10 | $168 |
| Medtronic(2 entities) | 3 | $153 |
| Merck | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $110 |
| Virtus Pharmaceuticals LLC | 4 | $73 |
| Pfizer | 4 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Azurity Pharmaceuticals, Inc. | 2 | $39 |
| Amgen | 1 | $35 |
| Nalu Medical, Inc. | 1 | $34 |
| Sentynl Therapeutics, Inc. | 2 | $33 |
| Innovation Technologies Inc | 1 | $25 |
| IBSA Pharma Inc. | 1 | $23 |
| MDD US Operations, LLC | 1 | $18 |
| Abbott | 1 | $17 |
| Valinor Pharma, LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,654 in reported general payments places this provider in the 20th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,882 | $150,280 |
| RelistorMethylnaltrexone Bromide | 19 | $45,627 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,473 | $35,491 |
| MovantikNaloxegol Oxalate | 36 | $15,636 |
| LinzessLinaclotide | 19 | $10,137 |
| Xtampza ErOxycodone Myristate | 18 | $9,723 |
| Lidocaine | 96 | $9,544 |
| Gabapentin | 631 | $6,876 |
| Hysingla ErHydrocodone Bitartrate | 12 | $6,574 |
| ZtlidoLidocaine | 11 | $6,286 |
| OxycontinOxycodone Hcl | 16 | $5,478 |
| Oxycodone Hcl | 213 | $3,759 |
| Morphine Sulfate ErMorphine Sulfate | 144 | $3,374 |
| Tizanidine Hcl | 347 | $2,468 |
| Cyclobenzaprine Hcl | 283 | $2,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $110 | $45,62719 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $168 | $9,72318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Harvey
- Maged GuirguisNew Orleans$565K
- Suneil JollyKenner$107K
- John CefaluShreveport$71K
- Steve LeeSlidell$57K
- William WhyteShreveport$39K
- Paul HubbellMetairie$33K
- Ken EhrhardtHammond$22K
- Thomas BerryLacombe$21K
- Randall BrewerShreveport$19K
- Corey Ann ConnCovinton$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.